Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
First we will see the 8-k than the 10-K
I wrote R. Kane and told him we will see if the 8-k comes or not?
Remember once all final details are announced the final 8k will come on this:
XCHC Signs Historic Agreement with WOLASTOKWIK NeGoot-Gook, Maliseet Nation at Tobique of Eastern Canada that Allows Medical Cannabis Hospitals, Laboratories, Clinics, for Cannabinoid Research and Treatments, Open to the World, All in Full Compliance with Law The Agreement was effectuated by the Company's purchase of the twenty-five percent (25%) stake in a joint venture from Cannabis Science, Inc. (NASDAQ OTC: CBIS). Details of the Company's stock-based asset purchase will be released in a Form 8K to be filed promptly.
The symbol stays as usual no worry and we also will see the fillings no hurry step by step
try to buy mayby on your dreams
it is not allowed to go short without an borrowing contract.
and even risk and the cost is to high to do this on this level
I would say if CBIS goes to an higer level 0.25 - 0.30 than it would make sense.(maybe)
Just my opinion
hope for good trading day
greeeeeeeeeeeeeeeeeeeeeen again!
ohhhhhhhhhhhhh 0.055 greeeeeeeeeeeeeeeeen
Greeeeeeeeeeeeeeeeeeeeeen today closing 0.058
the 10-k is already price in
if the figures comes better then expected nothing to lose for me it's a win win Situation
ohhhhhh 0.03 0.02 0.01 no way 0.55 now
greeeeeeeeeeeeeeeeeeeeeeeeeen yes
And still on the same level as last week we will chatch them up in 1 Day
Greeeeeeeeeeeeeeeeeeeeeen today great cbis
Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
Why would Dr. McGrath's such a well known man joy Cannabis Science?
These people on board they have bigger view and understanding
It seem the rocket is fired soon
The 8-k will following shortly then you guys are done you will see
XCHC Signs Historic Agreement with WOLASTOKWIK NeGoot-Gook, Maliseet Nation at Tobique of Eastern Canada that Allows Medical Cannabis Hospitals, Laboratories, Clinics, for Cannabinoid Research and Treatments, Open to the World, All in Full Compliance with Law The Agreement was effectuated by the Company's purchase of the twenty-five percent (25%) stake in a joint venture from Cannabis Science, Inc. (NASDAQ OTC: CBIS). Details of the Company's stock-based asset purchase will be released in a Form 8K to be filed promptly.
Greeeeeeeeeeeeeeeeeeeeeeen again yes
Cannabis owns 5‘000‘000 Shares of XCHC this is fact.
8-K Cannabis Science, Inc. to acquire its rights and interest in the Joint Venture Operating Agreement (Exhibit 99.2) with dupetit Natural Products GmbH for total consideration of $175,000, including 5,000,000 common shares in the Company with a fair market value of $150,000 plus the assumption of up to $25,000 in liabilities. On December 12, 2012, Cannabis Science, Inc. signed an Addendum to Joint Venture Operating Agreement with dupetit Natural Products GmbH clarifying voting rights and compensation structure under the Agreement.
XCHC has 36’000’000 Shares outstanding that means CBIS has 15% on XCHC that is fact.
Fact is CBIS has automatically Operating participation with dupetit Natural Products GmbH
Dupetit Natural Products GmbH is a very well company in Europe
German
web2.cylex.de/firma-home/dupetit-natural-products-gmbh-7385591.html
English
www.dupetit.de/german/framer.htm
And fact is Phytia will come soon trough several piplines in Germany and Europe and the rest of the World who has permission
To sell the product
That means the money machine in Europe has started
CBIS 1 Dollar
Cbis has 5'000'000 Shared x-change confirmed by 8-k so Look at the xchc 19% plus
Short covering has startend now hopefully they dont get shares the hole Way up
This is the greeeen feeling
Dark greeeeeeeeeeeeeeeeeeeen yes
Greeeeeeeeeeeeeeen today
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
This is Reported to Securities and Exchange Commission in Washington CBIS is a real Company.
FORM 10-Q/A
On February 9, 2012, the Company signed a license agreement with Apothecary Genetics Investments LLC. to produce several Cannabis Science Brand Formulations for the California medical cannabis market. As well, Apothecary will provide research and development facilities with full circle operations including a California laboratory facility for internal research and development, along with 16 unique genetic strains specifically generated and maintained by a cancer survivor who recognizes the importance of proper growth and breeding. The Company earned a $25,000 license fee under the agreement for the period ended September 30, 2012.
In consideration of this agreement, on January 1, 2012, the Company entered into a 25 year management agreement with Dr. Mohammad Afaneh to act Chief Operating Officer of Cannabis Science, Inc. Dr. Afaneh received 28,500,000 common shares valued at $299,250 under this agreement. In addition, on February 10, 2012, Dr. Afaneh signed a management bonus agreement where he received 5,000,000 common shares valued at $185,000 as a signing bonus for entering into his management agreement. In addition, on January 1, 2012, the Company entered into a 25 year management agreement with Bret Bogue to act as Director of Horticulture and head of research and development. Mr. Bogue received 28,500,000 common shares valued at $299,250 under this agreement. In addition, on February 10, 2012, Mr. Bogue signed a management bonus agreement where he received 5,000,000 common shares valued at $185,000 as a signing bonus for entering into his management agreement. These common shares were issued on April 24, 2012.
On February 9, 2012, the Company acquired GGECO University, Inc. (“GGECO”), an online video-based medical cannabis education system, offering courses dealing with medical cannabis law, the benefits of medical marijuana, cooking, horticulture, and bud tending. Following the university's name change to Cannabis Science University, the Company hopes to use this platform to educate the general public, patients, and even those who have already been involved in the medical cannabis industry on the medical benefits of cannabis, how it is grown, how to use it safely, and the many applications or ways to administer the medication. In consideration of this agreement, the Company issued 25,000,000 common shares with a fair market value of $935,000 to the principals of GGECO and assumed net liabilities of $24,686. The preliminary valuation of GGECO acquisition totaling $984,686 has been allocated to intangibles as at September 30, 2012. These common shares were issued on April 24, 2012.
On March 21, 2012, the Company acquired Cannabis Consulting Inc. (“CCI Group”), which consists of a group of businesses operated by Robert J. Kane, including: all contracted rights, properties, patents, trademarks, and distribution rights and agreements pertaining to Cannabis Consulting Inc., Robert Kane Partners, Kaneabis Consulting, Kaneabis Fund, Kaneabis Report, and Kaneabis Radio. In conjunction with the acquisitions, Robert Kane was promoted to V.P. of Investor Relations for the Company. Consideration paid for the CCI Group was 1,000,000 common shares to be issued to the principal, Mr. Robert Kane with a fair market value of $147,000, in addition to 250,000 free-trading common shares for services rendered with a fair market value of $25,000, which was settled for cash in lieu of issuing shares. The preliminary valuation of the CCI Group acquisition totaling $147,000 has been allocated to intangibles as at September 30, 2012. These shares were issued on May 25, 2012.
On June 1, 2012, the Company signed a Share Purchase Agreement to acquire Goldsmith Health Care, Ltd. (“GHC”), a Nevada company. GHC operates TrimCare (www.trimcare.com), a health care facility which specializes in weight-loss programs, cosmetic procedures, nutritional supplements, hormone replacement therapy, along with other therapeutic treatments. The Company paid GHC $155,000 and 5,000,000 common shares, including $5,000 for the first month’s license fees as consideration for the purchase. Total consideration, including the fair market value of shares issued for the acquisition of GHC is $457,500. Other monthly consideration is due if additional locations are opened under the TrimCare brand. On July 31, 2012, Cannabis Science, Inc. filed a lawsuit against Ivan Goldsmith, M.D., Mona Dever-Goldsmith, and a Nevada professional corporation, Goldsmith Health Care, Ltd. (collectively, “Defendants”). Goldsmith Health Care, Ltd. currently operates under the trade name TrimCare. This action arises out of a failure of the parties to consummate a transaction which was memorialized through the executed share purchase agreement signed on June 1, 2012. Despite the Company’s transferring of the necessary purchase price (a combination of $150,000 and 5,000,000 shares of stock in the Company), Dr. Ivan Goldsmith and his company refused to consummate the transaction. The lawsuit seeks compensatory and consequential damages, as well as injunctive and declaratory relief. The lawsuit further seeks punitive damages against Mrs. Dever-Goldsmith for the intentional interference of a third party contract. The Company and Defendants entered into a legal court settlement on October 10, 2012. Under the settlement, the Company agreed to drop all actions against the parties and the Company and Goldsmith agreed to unwind the acquisition transaction, including Dr. Goldsmith returning all monies and stock issued to him and GHC.
On July 27, 2012, the Company entered into a Joint Venture Operating Agreement (“JV”) with Dupetit Natural Products GmbH (“DNPG”). Under the Agreement the Company is entitled to 90% of net operating profits of the JV. The Company issued 5,000,000 common shares with a fair market value of $260,000 to the principal of DNPG as consideration for the provision of dozens of hemp and cannabis based products. DNPG currently distributes and sells products throughout Europe.
On September 10, 2012, the Company entered into a Joint Venture Operating Agreement (“JV”) with Wolastokwik NeGoot-Gook, Maliseet Nation at Tobique (“WNGM”) and George Kattar. Under the JV, the Company is entitled to 25% of net operating profits from the JV, which will be focused on establishing a clinical laboratory, medicine production facility and treatment center on WNGM provided land and facilities at the Maliseet Nation. As consideration for the JV, the Company is issuing 1 million common shares to WNGM and Mr. Kattar. The shares were issued on November 15, 2012.
What's wrong with the 8-k
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: February 21, 2013
The X-Change Corporation
(Exact name of small business issuer as specified in its charter)
Commission File Number: 002-41703
Nevada 90-0156146
(State of incorporation) (IRS Employer ID Number)
12655 North Central Expressway, Suite 1000 Dallas TX 75243
(Address of principal executive offices) (Zip Code)
(888) 889-0888
(Registrant’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
Item 1.01 - Entry into a Material Definitive Agreement
On December 28, 2012, The X-Change Corporation filed a Current Report on Form 8-K reporting the following:
“On December 12, 2012, the Company entered into an Asset Purchase Agreement (Exhibit 99.1) with Cannabis Science, Inc. to acquire its rights and interest in the Joint Venture Operating Agreement (Exhibit 99.2) with dupetit Natural Products GmbH for total consideration of $175,000, including 5,000,000 common shares in the Company with a fair market value of $150,000 plus the assumption of up to $25,000 in liabilities. On December 12, 2012, Cannabis Science, Inc. signed an Addendum to Joint Venture Operating Agreement with dupetit Natural Products GmbH clarifying voting rights and compensation structure under the Agreement.
Under the Joint Venture Operating Agreement, the Company has acquired a 90% interest in all products, brands and trademarks in dupetit Natural Products GmbH and an equivalent participation in net operating profits worldwide.”
Item 4.01 - Changes in Registrant’s Certifying Accountant.
Resignation of S. W. Hatfield, CPA's
On February 21, 2013, the Board of Directors of the Company was notified by it's auditors, S. W. Hatfield, CPA (SWHCPA) of Dallas, Texas that, as a result of the Asset Purchase Agreement with Cannabis Science, Inc., principally including the Joint Venture Operating Agreement with dupetit Natural Products GmbH (a Germany-based company), as reported in a Current Report on Form 8-K filed on or about December 28, 2012, SWHCPA would not stand for reappointment as the Company’s auditing firm for the year ended December 31, 2012.
The Company's Board of Directors has accepted the pending resignation of SWHCPA.
No accountant's report on the financial statements for either of the past two (2) years contained an adverse opinion or a disclaimer of opinion or was qualified or modified as to uncertainty, audit scope or accounting principles, except for a going concern opinion expressing substantial doubt about the ability of the Company to continue as a going concern.
During the Company's two most recent fiscal years (ended December 31, 2011 and 2010) and from January 1, 2012 to the date of this Report, there were no disagreements with SWHCPA on any matter of accounting principles or practices, financial disclosure, or auditing scope or procedure. For the years ended December 31, 2011 and 2010, and from January 1, 2012 through the date of this report, there were no “reportable events” as that term is described in Item 304(a)(1)(v) of Regulation S-K.
The Company provided SWHCPA with a copy of the foregoing disclosure and requested SWHCPA to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of SWHCPA’s letter dated February 21, 2013 is attached as Exhibit 16.1 in this filing.
The Company anticipates appointing successor auditors in the near future and will file the required Current Report on Form 8-K concurrent with that event.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
16.1 Letter from S. W. Hatfield, CPA
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
The X-Change Corporation
Dated: February 21, 2013 By: /s/ R. Wayne Duke
R. Wayne Duke
Chief Executive Officer
and Chief Financial Officer
New Medical MJ R&D Facility
US company to partner with Canadian Maliseet First Nation Tribe
A US medical marijuana company is moving full speed ahead with plans to build a first-of-its-kind cannabis campus that will include a treatment center, hospital facilities, a lab for research and product development and a cultivation site that will grow both MMJ and hemp.
The X-Change Corp. – one of the few publicly traded companies in the medical cannabis space (ticker symbol XCHC) – hopes to one day treat patients from around the world at the facility, offering cannabis-based remedies for their ailments.
How is this possible, given that marijuana is still illegal federally and state MMJ laws don’t cover these types of operations? The X-Change Corp. plans to build the campus on a big swath of land in New Brunswick, Canada, belonging to the Maliseet First Nation, the indigenous people of the region. The tribe – which has its own government and laws – has agreed to partner with the firm and the two sides are now hammering out details, including a projected timeline and the overall scope of the project. The partnership allows The X-Change Corp. to avoid the legal issues that prevent it from building such a facility elsewhere in Canada or the US – though there are still many challenges involved.
The X-Change Corp. actually bought the rights to the project from another US company, Cannabis Science, which planned to move forward with the development last year but has been unable to do so because of competing priorities.
Robert Kane, who is president of The X-Change Corp. and also handles investor relations for Cannabis Science, spoke with Medical Marijuana Business Daily about the project and what it means for the future of the marijuana business. Following are excerpts of that conversation:
Has CBIS applied for a patent for their formulars? NO
CBIS is only a drug development company. These models would possilbly come from PHYTIVA in the future.
CBIS will applie FDA for US market,CATN for Canada,EATN for Europe I believe that some requests are going trough.
If they all reject the applications CBIS have to make a decision on what to do next.Don't think that is possible based on they board and the emergency crisis situation of Kaposi. Futhermore, its the National Clinical Trial Groups that they work through first with the trials.
What are the difference to other MJ stocks. For Example MJNA is not even a reporting company.And all others are jokes.
Expenses are paid thru managing consultant at this time and that is normal for biotech. Not what it looks like on face value.
So you telling us all of the Managment are liar and they do nothing? please prove
Name Titel
1) Robert J Melamede President/CEO
2) Richard Cowan CFO/Secretary
3) Mohammad Afaneh "Moe" Chief Operations Officer
4) Richard Ogden Chief Scientific Officer
5) Robert Kane "Bob" VP:Investor Relations
6) Chad S Johnson General Counsel
I do not understand hammered most MJ are hammered today so what?
What's this Dupetit Natural Product do they sell nothing they do
an Cbis aquired 90% and is an 8-K
On December 28, 2012, The X-Change Corporation filed a Current Report on Form 8-K reporting the following:
“On December 12, 2012, the Company entered into an Asset Purchase Agreement (Exhibit 99.1) with Cannabis Science, Inc. to acquire its rights and interest in the Joint Venture Operating Agreement (Exhibit 99.2) with dupetit Natural Products GmbH for total consideration of $175,000, including 5,000,000 common shares in the Company with a fair market value of $150,000 plus the assumption of up to $25,000 in liabilities. On December 12, 2012, Cannabis Science, Inc. signed an Addendum to Joint Venture Operating Agreement with dupetit Natural Products GmbH clarifying voting rights and compensation structure under the Agreement.
Under the Joint Venture Operating Agreement, the Company has acquired a 90% interest in all products, brands and trademarks in dupetit Natural Products GmbH and an equivalent participation in net operating profits worldwide.”
CBIS is a drug development company developing CS TATI 1 and CS BCC - As with any drug development company and any company you are always investing in management. CBIS's formulations must be converted into a product, then things go well with NCTG and then the FDA.
CBIS also owns shares of XCHC and participates that way in the OTC market where the lip balm , skin creme and other cannabinoid based OTC markets are sold. www.phytiva.com
That's the story and nothing else
Nuvilex, Inc. Another Biotech Changing the Face of Medical Marijuana
2013-03-14 12:30:01.654 GMT
Nuvilex, Inc. Another Biotech Changing the Face of Medical Marijuana
NEW YORK, NY -- (Marketwire) -- 03/14/13 -- Nuvilex, Inc. (OTCQB:
NVLX), an international biotechnology and clinical stage provider of natural products and cell and gene therapy solutions for the treatment of diseases, has established a subsidiary in the Medical Marijuana industry.
Stock House Group, a full service investment relations firm focused on research, awareness and content development takes a look into the company that's giving the Medical Marijuana sector another biotech that will help to legitimize the drug for medicinal purposes.
In the U.S., there has always been a raised eyebrow in the room when it comes to using marijuana for medicinal purposes, but it's slowly eroding with more and more states passing legislation in favor of the use of marijuana for health reasons.
Make no mistake about it, medical marijuana is big business and prescription cannabis is now available in 18 states, the nation's capital, and eleven more states are considering legalizing the drug medically as well. The numbers are staggering -- in this country, we're talking about a $1.7-billion medical marijuana market and growing rapidly.
Marijuana's reputation is well documented and the once raised eyebrow at the mere mention of passing laws allowing its use is now starting to lower a bit as positive press defines the amazing benefits that can be realized from the drug. It will be the research and studies done by biotechnology companies like Nuvilex Inc. (OTCQB: NVLX) subsidiary, Medical Marijuana Sciences, Inc. and Cannabis Science, Inc. that helps change the image of marijuana from solely a drug to a medicine.
When serious diseases like brain, pancreatic, and other forms of cancer are diagnosed, patients aren't too concerned where a cure comes from, so Nuvilex, Cannabis Science and other biotechs are hard at work discovering the medical advantages of marijuana.
Low volume chart will change to a buy signal
Something big is coming?
this are my questions to the management Robert J.Kane no answer until today
1 CBIS have to have a product to put in the medbox before one can share revenue. What can CBIS share?
2. I’m still waiting for the first product today 20 february 2013 could you please tell me where I can buy the product?
3. Some firms have done the homework such as MJNA share price increased 3.5 times
4. What’s the strategy or business plan for 3 months and for the hole year.
5. Dilution has increased since Dec 2009 23.6 times makes me worry.
Hi to all
I was a long time away could some one tell me what's happen to the 4 Patient and the Biobsy Report I could not find the 4 patient on the web side what's happen to this people?????
Hi to all
I was a long time away could some one tell me what's happen to the 4 Patient and the Biobsy Report I could not find the 4 patient on the web side what's happen to this people?????
News
Cannabis Science Appoints Former GlaxoSmithKline Global Director of HIV Research Dorothy Bray, Ph.D., to Scientific Advisory Board Focusing on CS-TATI-1 and Other Emerging Scientific Investigations
Business Wire
COLORADO SPRINGS, Colo. -- June 14, 2012
Cannabis Science Inc (CBIS) announced today the appointment of Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, to the Company’s Scientific Advisory Board.
Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Director, Clinical Development HIV, GlaxoSmithKline, UK,
Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA:
Principal Clinical Research Scientist, Antivirals, Glaxo Wellcome, UK and USA:
Senior Clinical Research Scientist, HIV, The Wellcome Foundation, UK
Dr. Bray’s extensive experience in the field of HIV drug development will compliment Cannabis Sciences’ prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitor. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.
“It is highly commendable that Cannabis Science has made a commitment to develop a robust research program to further understand potent effects of cannabinoids on HIV TAT via cannabinoid 2 receptors and to translate these into therapeutically active products against HIV infection” stated Dr. Bray.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
“We are thrilled to welcome Dr. Bray to our Scientific Advisory Board. We are confident that her expertise in HIV research, drug development and marketing, as well her extensive knowledge in the HIV field, will greatly enhance our suburb group of scientific experts as we launch our Cannabinoid HIV TAT inhibitor platform,” states Dr. Robert Melamede, Ph.D. President & CEO Cannabis Science Inc.
About CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About HIV
HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and is creating a pressing need to develop new HIV drugs.
The U.S. government invests billions of dollars a year in HIV/AIDS research, treatment and care through a variety of programs. The Ryan White CARE Act, which funds the treatment and care of people living with HIV in the U.S., totals $2.3 billion a year. Among its many other contributions to fighting HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S. Military HIV Research Program and approximately $1 billion per year to The Global Fund to Fight AIDS, Tuberculosis and Malaria.
Pharmaceutical sales to treat HIV equal US $10.6 billion annually. Treatment cost per patient in the U.S. for HIV antivirals alone is approximately US $15,000 a year.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com
-0- Jun/14/2012 12:51 GMT
News out
Cannabis Science Appoints Former GlaxoSmithKline Global Director of HIV Research Dorothy Bray, Ph.D., to Scientific Advisory Board Focusing on CS-TATI-1 and Other Emerging Scientific Investigations
Business Wire
COLORADO SPRINGS, Colo. -- June 14, 2012
Cannabis Science Inc (CBIS) announced today the appointment of Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, to the Company’s Scientific Advisory Board.
Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Director, Clinical Development HIV, GlaxoSmithKline, UK,
Senior Medical Strategy Head, International Medical Affairs, Glaxo Wellcome Inc, USA:
Principal Clinical Research Scientist, Antivirals, Glaxo Wellcome, UK and USA:
Senior Clinical Research Scientist, HIV, The Wellcome Foundation, UK
Dr. Bray’s extensive experience in the field of HIV drug development will compliment Cannabis Sciences’ prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitor. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.
“It is highly commendable that Cannabis Science has made a commitment to develop a robust research program to further understand potent effects of cannabinoids on HIV TAT via cannabinoid 2 receptors and to translate these into therapeutically active products against HIV infection” stated Dr. Bray.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
“We are thrilled to welcome Dr. Bray to our Scientific Advisory Board. We are confident that her expertise in HIV research, drug development and marketing, as well her extensive knowledge in the HIV field, will greatly enhance our suburb group of scientific experts as we launch our Cannabinoid HIV TAT inhibitor platform,” states Dr. Robert Melamede, Ph.D. President & CEO Cannabis Science Inc.
About CS-TATI-1
Data published in March by researchers at the Mount Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2). Funding for the Mount Sinai study was provided by a National Institutes of Health (NIH) Clinical and Translational Science Award Grant. Cannabis Science’s research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. Cannabis Science will be pursuing a wide range of NIH based Federal Research Programs such as RO1’s, PO1’s and SBIRS which exist to support preclinical development of target validation and proof of concept studies. Cannabis Science will be pursing implementation of these studies through collaborations with leading scientific institutions. Cannabis Science will also be pursuing other clinical research collaborations including the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).
About HIV
HIV’s ability to mutate and reproduce itself even in the presence of antiretroviral drugs, has led to a growing rate of drug resistance. Increasing drug resistance is severely limiting treatment options for HIV patients around the world, increasing direct and indirect health costs, furthering the spread of drug resistant strains of HIV and is creating a pressing need to develop new HIV drugs.
The U.S. government invests billions of dollars a year in HIV/AIDS research, treatment and care through a variety of programs. The Ryan White CARE Act, which funds the treatment and care of people living with HIV in the U.S., totals $2.3 billion a year. Among its many other contributions to fighting HIV/AIDS globally, the U.S. provides $22.8 million annually to The U.S. Military HIV Research Program and approximately $1 billion per year to The Global Fund to Fight AIDS, Tuberculosis and Malaria.
Pharmaceutical sales to treat HIV equal US $10.6 billion annually. Treatment cost per patient in the U.S. for HIV antivirals alone is approximately US $15,000 a year.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com
-0- Jun/14/2012 12:51 GMT
Someone an idea
Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA) along with the positions in the US Public Health Service, and most recently, the Office of the US Secretary of Health and Human Services.
news out
Dr. Roscoe M. Moore Jr., U.S. Assistant Surgeon General (Retired), Appointed to Cannabis Science Scientific Advisory Board
Business Wire
COLORADO SPRINGS, Colo. -- June 07, 2012
Dr. Robert Melamede, President and CEO of Cannabis Science (CBIS), announced today that Roscoe Moore, DVM, PhD, MPH has been appointed to the Scientific Advisory Board.
About Dr Roscoe M. Moore Jr., DVM, MPH, Ph.D.,
Senior Scientific Advisory Board Member, CBIS
Dr. Moore served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA) along with the positions in the US Public Health Service, and most recently, the Office of the US Secretary of Health and Human Services.
Dr. Moore was named a Senior Fellow at the Potomic Institute in June 2003. He is currently the CEO and Vice Chairman of the Global Flu Consortium. As both a distinguished epidemiologist and veterinarian, Dr. Moore is particularly well positioned to help guide business planning and response to the Avian Flu. Dr. Moore brings to the Institute, deep experience and leadership through service that includes responsibilities as former Assistant United States Surgeon General, and as Rear Admiral in the U.S. Public Health Service. One of the world-renowned experts in epidemiology, Dr. Moore has been involved in the surveillance of emerging and re-emerging diseases worldwide as well as bioterrorism issues, and the safety of bioengineered foods.
Dr. Moore was the top-ranking veterinarian in all of the Uniformed Services, and served as the Associate Director for Development Support and African Affairs for the Department of Health and Human Services (HHS). In this capacity, Dr. Moore was the principal liaison between HHS and ministries of health for 53 countries in Africa, focusing on developing infrastructure and technical support to deliver preventive and curative human health needs for the continent.
Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; he also has received an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues.
“We are honored and excited that Dr. Roscoe M. Moore, Jr. is joining the Cannabis Science Scientific Advisory Board as the company enters into further clinical development of a wide range of commercial clinical investigations. His experience and knowledge in the medical field and his background within the FDA and US Public Health Services will be a tremendous asset to Cannabis Science. In addition to overseeing the development of CS-TATI-1, he will assist in our path towards human studies for HIV drug resistance and catabolic cachexia,” commented Dr Melamede. “Dr. Moore’s decision to join Cannabis Science's Scientific Advisory Board emphasizes the potential of phytocannabinod antiviral activity and our strong research and development efforts.”
CS-TATI-1 is in preclinical development intended to target HIV TAT, which is an important target for developing new HIV drugs, which are urgently needed. While there are currently 30 antiretroviral drugs on the market, increasing drug resistance to and toxicity from long term use of all existing medications. There is a high demand and need for new treatments to treat HIV drug resistance patients
Cannabis Science at AIDS 2012
AIDS 2012 is said to be the largest AIDS conference to date, with over 30,000 participants coming together from 200 different countries, Cannabis Science will be presenting at the World AIDS Institute’s Treatment Horizons satellite symposium on Cannabis Science’s HIV therapeutic research program based on the recent discovery by the Mount Sinai School of Medicine that phytocannabinoids inhibit a key HIV gene called TAT, which controls the virus’s ability to replicate.
Cannabis Science is also currently working with CBR International Corp. to develop a pre-IND application to the FDA that focuses on the use of CS-S/BCC-1 cannabinoid-based topical preparations for the treatment of basal and squamous cell carcinomas. CBR International’s Regulatory Strategy and Affairs Group are experienced in developing strategies for companies to proceed through various regulatory pathways to market in the United States and Europe. Their diverse team has the expertise in drugs, biologics and devices to efficiently navigate the regulatory approval process. They have Prepared and submitted over 100 INDs, IND, amendments, IDEs and Annual Reports to FDA. CBR has also Planned and participated in over 20 pre-IND/Pre-IDE meetings with FDA. As well, developed and implemented programs to prepare sponsors for Type A, B, and C meetings with FDA.
Cannabis Science released a press release dated June 5, 2012, titled “Cannabis Science Initiates HIV TAT Anti-Viral Drug Development Program; CS-TATI-1 Lead Hit Discovery Commenced for Pre-Clinical Proof of Concept Development” which, is featured on the AIDS 2012 Reunion Website: http://www.aids2012reunion.org/
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact:
Cannabis Science, Inc.
Dr. Robert J. Melamede
President & CEO
1-888-889-0888
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane
VP Investor Relations
1-561-234-6929
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com
-0- Jun/07/2012 08:03 GMT
buy now
you right he can speak just fliff flaff fluff
30,000 policy makers, researchers, clinicians and advocates from across the globe will be attending the world’s largest and premiere HIV/AIDS conference this year, which is being held in the U.S. for the first time in over two decades